IOL Chemicals and Pharmaceuticals · NSE: IOLCP · BSE: 524164
Q2 FY25 results · Jul–Sep 2024
IOL Chemicals and Pharmaceuticals reported revenue from operations of ₹525.75 crore (down 3.6% from Q2 FY24) and net profit of ₹19.15 crore (down 49.4% from Q2 FY24) for Q2 FY25 (Jul–Sep 2024), on a consolidated basis.
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 525.75 | 545.30 | −3.6% | 502.38 | +4.7% |
| Other income | 6.43 | 7.11 | −9.6% | 7.38 | −12.9% |
| Total income | 532.18 | 552.41 | −3.7% | 509.76 | +4.4% |
| Profit before tax | 25.94 | 51.18 | −49.3% | 39.52 | −34.4% |
| Net profit for the period | 19.15 | 37.87 | −49.4% | 29.97 | −36.1% |
| EPS, basic (₹) | 3.26 | 6.45 | −49.5% | 5.11 | −36.2% |
| Net margin (%) | 3.6 | 6.9 | 6.0 |
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 525.75 | 545.30 | −3.6% | 502.38 | +4.7% |
| Other income | 6.43 | 7.11 | −9.6% | 7.38 | −12.9% |
| Total income | 532.18 | 552.41 | −3.7% | 509.76 | +4.4% |
| Profit before tax | 25.94 | 51.10 | −49.2% | 39.23 | −33.9% |
| Net profit for the period | 19.15 | 37.79 | −49.3% | 29.68 | −35.5% |
| EPS, basic (₹) | 3.26 | 6.44 | −49.4% | 5.06 | −35.6% |
| Net margin (%) | 3.6 | 6.9 | 5.9 |
Consolidated
- Filed with BSE
- 14 Nov 2024, 17:52 IST
- Board meeting
- 14 Nov 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 14 Nov 2024, 17:52 IST
- Board meeting
- 14 Nov 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE